第二阶段

我们是谁

  • 4 月 5, 2022
    西妥昔单抗和维莫非尼联合 FOLFIRI 治疗 BRAF V600E 突变的晚期结直肠癌 (IMPROVEMENT)
  • 4 月 5, 2022
    Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
  • 4 月 5, 2022
    iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
  • 4 月 5, 2022
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
  • 4 月 5, 2022
    Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
  • 4 月 5, 2022
    给 HLA-A*11:01 患者注射用识别变异 RAS G12D 变异的小鼠 T 细胞受体转导的外周血淋巴细胞
  • 4 月 5, 2022
    对切除的高危结肠癌患者进行辅助加压腹腔内气溶胶化疗 (PIPAC)
  • 4 月 5, 2022
    Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
  • 4 月 5, 2022
    评估 FOLFIRINOX3 贝伐单抗治疗结直肠癌患者的疗效和安全性（FOLFIRINOX 3）
  • 4 月 5, 2022
    Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer